Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Lorazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.57 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.57 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.57 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.57 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.57 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.57 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.57 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.57 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.57 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.57 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.57 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.57 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.57 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.57 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.57 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | PGR | P06401 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Lorazepam SCHEMBL26962 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL26961 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29388543 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29516559 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| (S)-Lorazepam SCHEMBL120031 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL5271784 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29358033 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL13747464 | 0.99 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL28931472 | 0.97 | LMNA (0.97) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL5908139 | 0.97 | LMNA (0.97) | LMNAPGRMEN1ALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265875-A4 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMA (IL) | 2003-07-09 | — | — | EP | claimed |
| EP-1265875-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-18 | — | — | EP | claimed |
| US-6350870-B2 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICAL INDUSTREIS, LTD. (IL) | 2002-02-26 | — | — | US | claimed |
| US-20010039340-A1 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICALS USA, INC. | 2001-11-08 | — | — | US | claimed |
| WO-2001066062-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMAQCEUTICAL INDUSTRIES LTD. (IL) | 2001-09-13 | — | — | WO | claimed |
| WO-2005054211-A1 | A METHOD OF PURIFICATION OF LORAZEPAM | ZENTIVA, A.S. (SK) | 2005-06-16 | — | — | WO | disclosed |
| EP-1265875-A4 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMA (IL) | 2003-07-09 | — | — | EP | disclosed |
| EP-1265875-A4 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMA (IL) | 2003-07-09 | — | — | EP | disclosed |
| EP-1265875-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265875-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066062-A3 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMAQCEUTICAL IND LTD (IL) | 2002-04-18 | — | — | WO | disclosed |
| US-6350870-B2 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICAL INDUSTREIS, LTD. (IL) | 2002-02-26 | — | — | US | disclosed |
| US-6350870-B2 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICAL INDUSTREIS, LTD. (IL) | 2002-02-26 | — | — | US | disclosed |
| US-20010039340-A1 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICALS USA, INC. | 2001-11-08 | — | — | US | disclosed |
| US-20010039340-A1 | Process for preparing pure crystalline lorazepam | TEVA PHARMACEUTICALS USA, INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2001066062-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMAQCEUTICAL INDUSTRIES LTD. (IL) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066062-A2 | PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM | TEVA PHARMAQCEUTICAL INDUSTRIES LTD. (IL) | 2001-09-13 | — | — | WO | disclosed |